

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KKR Biosimilar L.P.</u> (Last) (First) (Middle) <u>C/O KOHLBERG KRAVIS ROBERTS & CO.</u> <u>L.P., 9 WEST 57TH STREET, SUITE 4200</u> (Street) <u>NEW YORK NY 10019</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc. [CHRS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/12/2014</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/12/2014		C		2,499,499	A	(1)	2,499,499	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series C Preferred Stock	(1)	11/12/2014		C		2,499,499		(1)	(3)	Common Stock	2,499,499	\$0.00	0	I	See Footnote(2)

1. Name and Address of Reporting Person*
KKR Biosimilar L.P.
 (Last) (First) (Middle)
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
 (Street)
NEW YORK NY 10019
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
KKR Biosimilar GP LLC
 (Last) (First) (Middle)
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
 (Street)
NEW YORK NY 10019
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
KKR Fund Holdings L.P.
 (Last) (First) (Middle)
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR Fund Holdings GP Ltd](#)

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR Group Holdings L.P.](#)

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR Group Ltd](#)

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR & Co. L.P.](#)

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR Management LLC](#)

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KRAVIS HENRY R](#)

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200

(Street)	NEW YORK	NY	10019
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
<u>ROBERTS GEORGE R</u>			
(Last)	(First)	(Middle)	
C/O KOHLBERG KRAVIS ROBERTS & CO.			
L.P., 9 WEST 57TH STREET, SUITE 4200			
(Street)	NEW YORK	NY	10019
(City)	(State)	(Zip)	

Explanation of Responses:

1. The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering.
2. Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.
3. Not applicable.

Remarks:

The Reporting Persons may have been deemed to have been ten percent owners of the Issuer's common stock as calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934 (the "Exchange Act") prior to the automatic conversion of all of the outstanding preferred stock of the Issuer immediately prior to the consummation of the initial public offering of the Issuer. This report shall not be deemed an admission that any such Reporting Person is subject to Section 16 of the Exchange Act. Each of the Reporting Persons (other than KKR Biosimilar L.P.) disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than KKR Biosimilar L.P.) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Report does not reflect shares of common stock of the Issuer purchased by KKR Biosimilar L.P. in the initial public offering following conversion of all of the outstanding preferred stock of the Issuer.

KKR BIOSIMILAR L.P. By:
KKR Biosimilar GP LLC, its
general partner By: /s/ Terence
Gallagher Name: Terence 11/14/2014
Gallagher Title: Attorney-in-fact
for William J. Janetschek, Chief
Financial Officer

KKR BIOSIMILAR GP LLC
By: /s/ Terence Gallagher Name:
Terence Gallagher Title: 11/14/2014
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR FUND HOLDINGS L.P.
By: KKR Group Limited, the
general partner of a general
partner By: /s/ Terence 11/14/2014
Gallagher Name: Terence
Gallagher Title: Attorney-in-fact
for William J. Janetschek,
Director

KKR FUND HOLDINGS GP
LIMITED By: /s/ Terence
Gallagher Name: Terence 11/14/2014
Gallagher Title: Attorney-in-fact
for William J. Janetschek,
Director

KKR GROUP HOLDINGS L.P.
By: KKR Group Limited, its
general partner By: /s/ Terence
Gallagher Name: Terence 11/14/2014
Gallagher Title: Attorney-in-fact
for William J. Janetschek,
Director

KKR GROUP LIMITED By: /s/
Terence Gallagher Name:
Terence Gallagher Title: 11/14/2014
Attorney-in-fact for William J.
Janetschek, Director

KKR & CO. L.P. By: KKR
Management LLC, its general
partner By: /s/ Terence
Gallagher Name: Terence 11/14/2014
Gallagher Title: Attorney-in-fact
for William J. Janetschek, Chief
Financial Officer

KKR MANAGEMENT LLC 11/14/2014

By: /s/ Terence Gallagher Name:

Terence Gallagher Title:

Attorney-in-fact for William J.

Janetschek, Chief Financial

Officer

HENRY R. KRAVIS By: /s/

Terence Gallagher Name:

11/14/2014

Terence Gallagher Title:

Attorney-in-fact

GEORGE R. ROBERTS By: /s/

Terence Gallagher Name:

11/14/2014

Terence Gallagher Title:

Attorney-in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.